These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 15019061

  • 1. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
    Kanakis I, Nikolaou M, Pectasides D, Kiamouris C, Karamanos NK.
    J Pharm Biomed Anal; 2004 Mar 01; 34(4):827-32. PubMed ID: 15019061
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
    Pectasides D, Farmakis D, Nikolaou M, Kanakis I, Kostopoulou V, Papaconstantinou I, Karamanos NK, Economopoulos T, Raptis SA.
    J Pharm Biomed Anal; 2005 Feb 07; 37(1):171-6. PubMed ID: 15664758
    [Abstract] [Full Text] [Related]

  • 3. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M, Takahashi S, Ogata E.
    Anticancer Res; 2003 Feb 07; 23(5b):4095-9. PubMed ID: 14666607
    [Abstract] [Full Text] [Related]

  • 4. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
    Lumachi F, Marino F, Fanti G, Chiara GB, Basso SM.
    Anticancer Res; 2011 Nov 07; 31(11):3879-81. PubMed ID: 22110213
    [Abstract] [Full Text] [Related]

  • 5. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE.
    J Natl Cancer Inst; 2005 Jan 05; 97(1):59-69. PubMed ID: 15632381
    [Abstract] [Full Text] [Related]

  • 6. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A, Stellos K, Matthaios D, Petrakis G, Parmenopoulou V, Babatsikou F, Matthaiou E, Theodosiadou E, Hountis P, Koutis C.
    J BUON; 2009 Jan 05; 14(3):463-72. PubMed ID: 19810140
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases.
    Morris PG, Fazio M, Farooki A, Estilo C, Mallam D, Conlin A, Patil S, Fleisher M, Cremers S, Huryn J, Hudis CA, Fornier MN.
    J Oral Maxillofac Surg; 2012 Dec 05; 70(12):2768-75. PubMed ID: 22330331
    [Abstract] [Full Text] [Related]

  • 11. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
    Tamiya M, Tokunaga S, Okada H, Suzuki H, Kobayashi M, Sasada S, Okamoto N, Morishita N, Matsuura Y, Miyamoto N, Hattori M, Taira K, Daga H, Takeda K, Hirashima T.
    Clin Lung Cancer; 2013 Jul 05; 14(4):364-9. PubMed ID: 23276824
    [Abstract] [Full Text] [Related]

  • 12. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 Jul 05; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

  • 13. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, Karamanos NK, Economopoulos T, Raptis SA.
    Anticancer Res; 2005 Jul 05; 25(2B):1457-63. PubMed ID: 15865105
    [Abstract] [Full Text] [Related]

  • 14. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer.
    Yokoyama T, Yamamoto M, Shima K, Suzuki K, Sako C, Ito G, Kume M, Maeda M.
    Respirology; 2005 Jun 05; 10(3):300-4. PubMed ID: 15955141
    [Abstract] [Full Text] [Related]

  • 15. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
    Generali D, Berruti A, Tampellini M, Dovio A, Tedoldi S, Bonardi S, Tucci M, Allevi G, Aguggini S, Milani M, Bottini A, Dogliotti L, Angeli A.
    Bone; 2007 Jan 05; 40(1):182-8. PubMed ID: 16935041
    [Abstract] [Full Text] [Related]

  • 16. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
    Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, Ruutu M, Purohit OP, Tähtelä R, Coleman RE.
    Calcif Tissue Int; 2007 Nov 05; 81(5):341-51. PubMed ID: 17874331
    [Abstract] [Full Text] [Related]

  • 17. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone.
    Cloos PA, Lyubimova N, Solberg H, Qvist P, Christiansen C, Byrjalsen I, Christgau S.
    Clin Lab; 2004 Nov 05; 50(5-6):279-89. PubMed ID: 15209436
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.